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Abstract 
Background: The high cost of commercial HIV-1 viral load tests for monitoring of 
patients on antiretroviral treatment limits their use in resource-constrained settings. 
Commercial genotypic antiretroviral resistance testing is even more costly, yet it 
provides important benefits.  
Objectives: We sought to determine the sensitivity and negative predictive value of a 
qualitative PCR targeting partial reverse transcriptase for detection of virologic failure  
when 5 patient specimens are pooled. 
Study Design: A total of 300 South African routine patient samples were included 
and tested in 60 pools of 5 samples each. A qualitative nested PCR was optimised 
for testing pools and individual samples from positive pools. All positive samples 
were sequenced to detect drug resistance-associated mutations. Results were 
compared to those of conventional viral load monitoring. 
Results: Twenty-two of 60 pools tested positive. Individual testing yielded 29 positive 
individual samples. Twenty-six patients had viral loads of above 1000 copies per 
millilitre. The pooling algorithm detected 24 of those 26 patients, resulting in a 
negative predictive value of 99.3%, and a positive predictive value of 89.7%. The 
sensitivity for detecting patients failing therapy was 92%, with a specificity of 98.9%. 
Of the patients failing first-line ART, 83.3% had NRTI and 91.7% NNRTI resistance 
mutations.  
Conclusions: The pooled testing algorithm presented here required 43% fewer 
assays than conventional viral load testing. In addition to offering a potential cost 
saving over individual viral load testing, it also provided drug resistance information 
which is not available routinely in resourced-limited settings. 
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1. Background 
The enormous increase in the number of patients receiving antiretroviral therapy 
(ART) worldwide is a remarkable success story but also poses a considerable 
burden on resource-limited countries due to the cost of drugs, medical care and 
laboratory monitoring [1]. 
As part of its public health approach, the World Health Organization (WHO) 
recommends non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line 
ART regimens for adult patients and for those failing first-line ART a boosted 
protease inhibitor (PI)-based second-line regimen [2,3]. This approach has been 
adopted by many countries, including South Africa [4]. ART failure may be 
determined in different ways. Monitoring of HIV viral load detects failure very early 
and is more specific than clinical and immunological (CD4 count) monitoring; 
therefore routine viral load monitoring is the gold standard and recommended where 
available [2,5]. However, the technical complexity of available viral load assays and 
their cost hamper access to viral load monitoring in most resource-limited settings 
[6,7]. 
Dried blood spots (DBS) prepared from blood obtained through skin pricks are widely 
used to diagnose HIV infection in infants [8], and can also be used for viral load 
monitoring [7,9,10], which may reduce overall cost and increase access. However 
the high cost of viral load testing still remains an obstacle. 
Pooled viral load testing can save costs by reducing the number of tests needed 
[11,12,13] and can be combined with the use of DBS [14,15]. However, a viral load 
value above a clinical threshold (in South Africa currently 1000 viral RNA copies/ml 
in line with current WHO guidelines) cannot ascertain the cause of treatment failure 
[16], which may be due to suboptimal drug levels secondary to insufficient 
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adherence or drug and food interactions etc., or due to drug resistant virus [14,17]. 
According to a recent WHO report, approximately 30% of patients failing first-line 
ART have no detectable resistance mutations [18] but are at risk of being 
unnecessarily switched to more costly and less well tolerated second-line ART 
regimens. 
In resource-rich countries, antiretroviral drug resistance (ADR) testing is used to 
determine whether virological failure is due to drug resistance. However, although 
the need for ADR testing has been recognised, and despite recently published 
guidelines, a lack of testing capacity and budget constraints seriously hamper their 
application [19].  
Recently, a novel approach combining testing of pooled samples by qualitative PCR 
with sequencing of positive samples was proposed [20]. If a pool tests positive, each 
sample in that pool is tested individually with the same assay and any positive 
sample is sequenced using the amplified product. This approach is very elegant in 
that it is more affordable than individual viral load monitoring through the use of 
pooling and of a qualitative instead of a quantitative PCR, while providing valuable 
additional information on the presence of resistance mutations for those who are 
failing treatment. 
 
2. Objectives 
This study aimed to validate and adapt this approach for a Southern African setting, 
where HIV-1 subtype C is most prevalent, with the specific aim of determining the 
sensitivity and negative predictive value the qualitative PCR targeting partial reverse 
transcriptase for detection of virologic failure when 5 patient specimens are pooled, 
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and to determine the prevalence of mutations detected by sequencing the PCR 
product of individual specimens from positive pools. 
 
3. Study Design 
3.1 Study Population 
Samples received at the diagnostic virology laboratory of the National Health 
Laboratory Service (NHLS) Tygerberg in Cape Town, South Africa, between May 
2013 and June 2013 for routine HIV viral load testing were sequentially selected if 
they met the following inclusion criteria: adult patient; on first-line ART; no HIV viral 
load testing in the previous 4 months; sufficient specimen volume left after routine 
testing. 
3.2 Specimens 
Routine viral load testing, using the Abbott RealTime HIV-1 assay with a limit of 
detection of 40 copies/ml, was performed on all samples as requested and residual 
specimens then used for the study. A total of 300 samples were included, pooled into 
60 pools of 5 samples each.  
The person performing the study testing was blinded to the routine HIV viral load 
result which was revealed only once the pooled testing algorithm was completed. 
3.3 Pooling of samples and nucleic acid extraction 
Pools consisted of 100µl of each of 5 individual samples, resulting in a total pool 
volume of 500µl.Nucleic acid extraction from pooled samples was performed using 
the NucliSENS®easyMAG® system (Biomérieux, Marcy l'Etoile, France). Of an 
elution volume of 100µl, 5µl were used for reverse transcription and first-round PCR. 
3.4 PCR amplification 
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Initially the primers from Tilghman [20] and a single-round PCR were used, but due 
to insufficient sensitivity for detecting viral loads below 10,000 copies/ml of HIV-1 
subtype C from pooled specimens, this approach was abandoned and a new PCR 
designed and optimised. 
This nested PCR uses previously described primers Mj3 and Mj4 [21] as outer 
primers and a new set of nested (inner) primers,4RT (amino acid position in RT 229 
→ 236) and 5RT long C (amino acid position in RT 52 → 62) [22].These were 
designed to amplify with high sensitivity a conserved region in HIV-1 group M viruses 
including subtype C, and for the short amplification product to allow efficient 
sequencing using the nested primers while including the most important resistance-
related mutations in the reverse transcriptase coding region (RT) of the pol gene. 
Primer sequences and positions are shown in Table 1. 
The first round is a one-step RT-PCR, with the reaction mixture consisting of 14µl of 
nuclease free water, 2µl each of Mj3 and Mj4 (10µM), 2µl of Superscript III Taq mix 
and 25µl of 2X reaction mix (a buffer containing 0.4mM of each dNTP, 3.2mM 
MgSO4), to give a final reaction volume of 50µl. The second round reaction mixture 
consisted of 11.25µl of nuclease free water, 5µl of 5X Go Flexi buffer, 0.5µl of 
dNTPs, 2µl of MgCl (25µM), 2µl each of 5RT long C and 4RT (10µM), 0.25µl of Go 
Taq polymerase and 2µl of amplified product from the first round. Thermal cycling 
was performed on the GeneAmp® PCR System 9700, Applied Biosystems (Foster 
City, CA, USA). The presence or absence of amplified product was assessed using 
agarose gel electrophoresis.  
3.5 Deconvolution of positive pools and genotypic resistance testing 
If a pool tested positive, all five individual samples contained in the pool were tested 
separately. For this, samples were re-extracted individually with the 
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NucliSENS®easyMAG® system, using 100µl of sample and 100µl elution volume. 
First and second round reactions were carried out as for the pooled testing. Any 
positive individual sample was subjected to standard Sanger sequencing using a 
validated in-house protocol (validated against the ABI Prism Dye Terminator Cycle 
sequencing kit), which has also been used in previous studies [17] and is currently 
the diagnostic method at Tygerberg Hospital, using the amplified second-round PCR 
product and 5RT long C and 4RT (the same forward and reverse primers used for 
second round amplification, respectively) as sequencing primers. The sequencing 
platform used was the 3130xl Genetic Analyzer, Applied Biosystems (Foster City, 
CA, USA). The Stanford HIV db Program, available fromhttp://hivdb.stanford.edu/, 
was used for sequence analysis and resistance interpretation. This allowed 
identification of the most common NNRTI and nucleoside reverse transcriptase 
inhibitors (NRTI) associated mutations [14,17]. Table 1 shows the primer sequences 
as well as the kits and equipment used. 
3.6 Evaluation of pooled testing results 
After pooled testing, deconvolution of positive pools and genotypic resistance testing 
of individual positive samples, results were compared to routine HIV viral load test 
results. In South Africa, virologic failure is defined as a viral load of 1000 copies per 
millilitre or greater [3]. 
 
4. Results 
Table 2 shows the ART data for the study population. The majority of patients were 
on the current first-line ART regimen in South Africa, consisting of tenofovir, 
lamivudine and efavirenz. 
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Twenty-two of the 60 pools were positive. Individual testing revealed 29 (9.7%) 
samples with a detectable viral load. Of these, 26 samples (8.7%) had viral loads of 
above 1000 viral RNA copies per millilitre and were therefore defined as failing ART. 
Pooled testing detected 24 of those 26 patients.The two samples that were missed 
were retested using the pools and individually, confirming the lack of amplification. 
Both patients were females on tenofovir-based ART regimens, with viral loads of 
8596 copies/ml and 38542 copies/ml, respectively. For the latter, residual extract 
was available for standard genotyping, which confirmed this particular strain to be 
genotype C. 
The negative predictive value of pooled testing was 99.3% and the sensitivity for 
detecting patients failing therapy 92%. Table 3 summarises the results of pooled 
testing. 
Most positive samples did have antiretroviral drug resistance-associated mutations. 
Figure 1 and Figure 2 illustrate the prevalence of various resistance mutations 
detected for NRTI and NNRTI, respectively. Of the patients failing first-line ART, 
83.3% had NRTI resistance and 91.7% had NNRTI resistance. The commonest 
NRTI mutations were M184V/I and K65R, with 75% and 25% among patients failing 
ART, respectively, while the commonest NNRTI mutation was K103N in 46% of 
failing patients. 
 
5. Discussion 
The pooled testing algorithm presented here was able to detect 24 of 26 adult 
patients failing first-line ART according to WHO and South African national criteria 
and provided drug resistance information on the failing patients. 
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Pooled viral load testing has been shown to decrease the cost of virological 
monitoring in adults on first-line ART who have a low prevalence of failure [14,23]. 
Qualitative rather than quantitative detection of failure has previously been shown to 
reduce the cost of virological monitoring [24], and sequencing of the reverse 
transcriptase coding region of the pol gene alone likewise reduces costs compared 
to longer sequences [25]. 
An approach that combines pooled testing, qualitative detection of virological failure 
and reverse trancriptase-only sequencing for detection of first-line NNRTI-based 
ART regimen failure was developed by Tilghman et al in 2012 [20]. Pools consisting 
of five individual specimens are tested by qualitative PCR, which could be followed 
by deconvolution of positive pools and sequencing of individual positive specimens. 
In their study, deconvolution of positive pools was not done due to insufficient 
sample volumes, but this proof-of-principle experiment has shown promise in the 
USA [20]. However, this approach may in fact be needed more urgently in resource-
constrained settings where virological monitoring is not available widely at present. 
We therefore validated this approach in a Southern African context, where HIV-1 
subtype C is most prevalent and patient characteristics differ markedly from 
industrialised countries. We found poor amplification when using the primers from 
Tilghman et al, 2012, in our setting where subtype C dominates, which can be 
explained by too many mismatches when aligned with HIV-1 subtype C in silico. We 
therefore designed primers, 5RT long C and 4RT, primarily for subtype C but also 
considering other group M subtypes, as our inner primers, while using previously 
described primers, Mj3 and Mj4 [21], as outer primers.  
We were able to achieve a sensitivity of 92% and a positive predictive value of 
89.7% for detecting patients who were failing ART according to WHO criteria (i.e. 
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with a viral load of > 1000 copies / ml), missing two patients out of a total of 26 with 
ART failure, with a specificity of 98.9%. The most likely reason for the lower 
sensitivity is probably primer-template mismatches, which are a common problem 
with amplification and sequencing of a highly divergent virus [26,27], where intra-
clade differences in the RT region for subtype C are nearly 6% [26], possibly 
explaining the reason for the slightly lower sensitivity for detecting ART failure 
compared to the Tilghman study in North America, where subtype B is predominant. 
However, with a negative predictive value of greater than 99%, and being able to 
provide drug resistance information for patients failing first-line ART, our study 
provides proof of principle that the concept developed by Tilghman et al. is viable in 
a Southern African context and possibly beyond. 
Table 4 highlights the potential cost savings and benefits of the pooling algorithm 
over individual viral load monitoring. Although there may be potential cost savings 
based on reagent costs and number of tests, the most substantial benefit is likely to 
be earlier and appropriate switching to second-line ART, limiting switching of patients 
to those who indeed have antiretroviral drug resistance and avoiding switching to 
more expensive and less well tolerated second-line ART unnecessarily in the 
absence of resistance mutations. A recent WHO report stated that in approximately 
70% of first-line ART failure cases, at least one drug resistance mutation was 
detected. Conversely, in the remaining 30%, no resistance mutations were detected 
[18,28]. In countries where DRT is not available, these patients may have been 
switched unnecessarily to more expensive second-line treatment. Therefore, 
preventing the latter could potentially result in a cost saving. 
In addition, some studies have shown that delaying switching to second-line ART 
after first-line failure is associated with increased risk of failing second-line ART, with 
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poorer patient outcomes [29,30], whereas other studies suggest that NRTI 
resistance may not matter in this regard [31,32]. This notwithstanding, there is 
uncertainty regarding the long term durability of second-line ART in the presence of 
significant NRTI resistance mutations. 
One of the limitations of this study stems from a lack of a full cost effectiveness 
analysis. This would be needed in future to prove the cost benefit and convince 
policymakers in poorer countries that the qualitative pooling algorithm including 
resistance testing could allow for cheaper, more efficient, and more clinically useful 
ART monitoring. 
Another limitation is that in the interest of sensitivity and sequencing using only two 
primers, two major reverse transcriptase resistance associated mutations were 
excluded: M41L, which confers low level resistance to AZT or D4T, and M230L, a 
major NNRTI mutation. In our setting, M41L occurs in only 2.8% of patients failing a 
first-line regimen containing a NNRTI and a thymidine analogue and was the only 
thymidine analogue mutation in only ¼ of these patients [17]. M230L occurs in 6.5% 
of patients who fail an EFV-based regimen [17], however it very rarely (0.1%) occurs 
as the only NNRTI mutation (G. van Zyl, 2014, unpublished results from 858 
sequences from patients failing an EFV regimen). The exclusion of these mutations 
therefore should have minimal impact on the clinical predictive value of our 
genotyping results. 
In dealing with the dramatic consequences of the HIV pandemic, early detection of 
the presence or absence of drug resistance mutations in patients failing ART is 
vitally important to minimise the cost of delayed or unnecessary switching to second-
line therapy, especially in resource limited settings. The pooling algorithm first 
presented by Tilghman et al in 2012 [20], and here adapted for a Southern African 
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context, is a potential solution to this problem, and provides an affordable approach 
to detecting first-line therapy failure and simultaneously differentiating poor 
adherence to medication from major drug resistance mutations as the cause of 
failure.  
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Table 1.Primers, reagents and equipment. 
 
First round one-step RT-PCR Second round PCR 
Forward Primer (Mj3)  
5’- AGTAGGACCTACACCTGTCA -3’ 
HXB2 position - 2480 → 2499 
Forward primer (5RT long C) 
5’CTGAAAATCCATATAACACTCCAATATTTGY-3’ 
HXB2 position - 2704 → 2734 
Reverse Primer (Mj4) 
5’- CTGTTAGTGCTTTGGTTCCTCT-3’ 
HXB2 position - 3399 → 3420 
Reverse Primer (4RT) 
5’- GATGGAGTTCATACCCCATCCA- 3’ 
HXB2 position - 3234 → 3255 
Kit: 
SuperScript™ III One-Step RT-PCR 
System, Invitrogen (Carlsbad, CA- 
USA) 
Kit: 
GoTaq® DNA Polymerase,Promega (Madison, WI, 
USA) 
RT-PCR – reverse transcription polymerase chain reaction 
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Table2. ART data for n= 300 patients included in the study 
 
 
 
 
CD4  count         
(nX106 per 
litre)    
Males 
n= 87 (%) 
Females 
n= 213 (%) 
Total 
n= 300 (%) 
 
> 500 
 
20 (23) 
 
109 (51) 
 
129 (43) 
 
351 - 500 
 
34 (39) 
 
45 (21) 
 
79 (26) 
 
200 - 350 
 
21 (24) 
 
44 (20) 
 
65 (22) 
 
< 200 
 
12 (14) 
 
15 (7) 
 
27 (9) 
ART Regimen    
 
ART 1 
 
52 (60) 
 
111 (52) 
 
163 (54) 
 
ART 2 
 
2 (2) 
 
17 (8) 
 
19 (6) 
 
ART 3 
 
1 (1) 
 
27 (13) 
 
28 (9) 
 
ART 4 
 
20 (23) 
 
22 (10) 
 
42 (14) 
 
ART 5 
 
10 (11) 
 
8 (4) 
 
18 (6) 
 
ART 6 
 
2 (2) 
 
28 (13) 
 
30 (10) 
 
ART regimen 1 = tenofovir, lamivudine, efavirenz 
ART regimen 2 = zidovudine, lamivudine, efavirenz 
ART regimen 3 = zidovudine, lamivudine, nevirapine 
ART regimen 4 = stavudine, lamivudine, efavirenz 
ART regimen 5 = stavudine, lamivudine, nevirapine 
ART regimen 6 = tenofovir, lamivudine, nevirapine 
 
 21
Table 3.Results of pooled testing. 
 
 
No. of sample tested in total 300 
No. of individual samples tested negative 271 
No. of individual samples tested positive 29 
No. of individual samples with VL > 1000 cps/ml 26 
No. of pools tested in total 60 
No. of pools tested negative 38 
No. of pools tested positive 22 
No. of samples with VL > 1000 cps /ml detected by pooled testing 24 
Sensitivity for detecting samples with > 1000 cps/ml 92.0 % 
No. of true negative individual samples 269 
Negative predictive value 99.3% 
VL –HIV viral load ; cps/ml – copies per millilitre  
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Table 4. Potential cost saving and benefits of pooling assay 
 
 
Current ART monitoring in South Africa 
 
 
Pooling Algorithm 
 
Approximate reagent cost 
 
300 patients  300 viral load tests 
 
Reagent cost per reaction ~ R100 
 
Therefore, total reagent cost ~ R30000 
 
 
Approximate reagent cost 
 
300 patients  60 pools ; 22 positive pools 
 
22 X 5 samples per positive pool = 110 
Total no. of reactions = 170 
Reagent cost per PCR reaction ~ R100 
Therefore total reagent cost for PCR ~ R17000 
 
Reagent cost per test for DRT ~ R172 
Therefore total reagent cost for 29 tests ~ R4988 
 
Therefore total reagent cost for pooling algorithm = 
R21988 
 
 
Advantages 
 
Gold standard for virological monitoring 
 
 
Advantages 
 
Potentially cheaper than viral load monitoring 
 
Drug  resistance information provided 
 
Excellent negative predictive value 
 
May allow for earlier switching to second-line 
therapy 
 
May prevent unnecessary switching to second-line 
therapy 
 
 
Disadvantages 
 
Expensive 
 
No drug resistance information 
 
 
 
Disadvantages 
 
Not as sensitive for detecting patients with viral 
loads > 1000 copies/ml 
 
 23
Figure 1: Prevalence of NRTI resistance mutations detected using pooling method 
algorithm 
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Figure 2: Prevalence of NNRTI resistance mutations detected using pooling method 
algorithm 
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(the end) 
 
 
